Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study
Yasushi Isobe; Tsuyoshi Muta; Yosuke Masamoto; Go Yamamoto; Shingo Kurahashi; Yoshihiro Kameoka; Shuichi Ota; Eri Matsuki; Kazutaka Ozeki; Takanori Toyama; Naoki Takahashi; Takahiro Kumode; Nobuyuki Aotsuka; Takuro Yoshimura; Hideto Tamura; Ai Omi; Kazuhiro Shibayama; Yuma Fujimori; Kensuke Kojima; Jun Takizawa; Hirokazu Nagai; Junji Suzumiya; Sadao AokiShow moreShow less
1. Department of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital; 2. Department of Transfusion Medicine Clinical Laboratory, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital; 3. Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital; 4. Department of Hematology, Toranomon Hospital; 5. Department of Hematology and Oncology, Toyohashi Municipal Hospital; 6. Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine and Faculty of Medicine; 7. Department of Hematology, Akita Red Cross Hospital; 8. Department of Hematology, Sapporo Hokuyu Hospital; 9. Division of Hematology, Department of Medicine, Keio University School of Medicine; 10. Department of Hematology and Oncology, JA Aichi Konan Kosei Hospital; 11. Department of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital; 12. Department of Hematology, International Medical Center, Saitama Medical University; 13. Department of Hematology and Rheumatology, Kindai University Hospital; 14. Department of Hematology and Oncology, Japanese Red Cross Narita Hospital; 15. Department of Hematology, Osaka City General Hospital; 16. Department of Hematology, Dokkyo Medical University Saitama Medical Center; 17. Department of Hematology, Nippon Medical School; 18. Department of Medical Affairs, Johnson & Johnson Innovative Medicine; 19. Statistics & Decision Sciences Japan, Johnson & Johnson Innovative Medicine; 20. Department of Hematology, Kochi Medical School, Kochi University; 21. Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine; 22. Department of Hematology, National Hospital Organization Nagoya Medical Center; 23. Department of Hematology, Koga Community Hospital; 24. Department of Medical Technology, Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences; 25. Department of Hematology, Niigata Minami HospitalShow moreShow less
Acute promyelocytic leukemia with clonal hematopoiesis: a case study of APL in complete molecular remission transitioning to MDS/MPN and its clinical implications
Anetta Marcinek; Katrin Schweneker; Manja Meggendorfer; Torsten Haferlach; Frank DickerShow moreShow less
1. MLL Munich Leukemia LaboratoryShow moreShow less
Chronic myelomonocytic leukemia associated with lymphoid neoplasms
Julia Bannatyne; Iñigo Romon; Juan J. Domínguez; Andrés Insunza; Enrique M. Ocio; Montserrat BrizShow moreShow less
1. Hospital Universitario Marqués de Valdecilla-IDIVAL; 2. Facultad de Medicina, Universidad de CantabriaShow moreShow less
The APLC 2025 consensus recommendations on the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia
Carol Yuk Man Cheung; Nurul Aidah Abdul Halim; Gin Gin Gan; Ying Wang; Hein Than; Jie Jin; Bor Sheng Ko; Soo Min Lim; Wasithep Limvorapitak; Ting Liu; Pak Ling Lui; Melissa Gaik Ming Ooi; Sreekanth Sampath Venkata; Adisak Tantiworawit; Gee Chuan Wong; Su Peng Yeh; Jae-Ho Yoo; Ashley P. NgShow moreShow less
1. Queen Mary Hospital; 2. Singapore General Hospital; 3. University Malaya Medical Centre; 4. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; 5. First Affiliated Hospital of Zhejiang University College of Medicine; 6. National Taiwan University Hospital; 7. Hospital Sultanah Aminah; 8. Thammasat University Hospital; 9. West China Hospital of Sichuan University; 10. National University Cancer Institute; 11. Tan Tock Seng Hospital; 12. Chiang Mai University Hospital; 13. China Medical University Hospital; 14. Seoul St Mary’s Hospital, The Catholic University of Korea; 15. Peter MacCallum Cancer Centre; 16. The Royal Melbourne HospitalShow moreShow less
Lower baseline eosinophil counts are associated with inferior survival in Mantle cell lymphoma
Kacper Kopeć; Mateusz Fałek; Julia Piotrowska; Adrian Ławski; Julia Rojek; Kacper Pawlak; Maria Woźniak; Marta Czajkowska; Olga Raczyńska; Tadeusz Robak; Jan Wojdal; Paweł Robak; Joanna Góra-Tybor; Damian MikulskiShow moreShow less
1. Department of Hemato-Oncology and Internal Medicine, Copernicus Memorial Hospital; 2. Department of Hematology, Medical University of Lodz; 3. Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital; 4. Department of General Hematology and Internal Medicine, Provincial Multi-Specialized Oncology and Trauma Center; 5. Department of Hematology and Transplantology, Copernicus Memorial HospitalShow moreShow less
Single-Cell RNA sequencing analysis of cellular heterogeneity and microenvironment-driven signaling networks in acute myeloid leukemia
Lo-Jei Ching; Chia-Hao Wang; Wen-Liang Lo; Yu-Jou Cheng; Huan Ou-Yang; Yuan-Tzu Lan; Pin-I Huang; Yi-Wei Chen; Yen-Hung Yao; Shih-Hwa Chiou; Yi-Ping Yang; Ping-Hsing Tsai; Po-Shen KoShow moreShow less
1. Department of Medical Research, Taipei Veterans General Hospital; 2. Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University; 3. School of Medicine, College of Medicine, National Yang Ming Chiao Tung University; 4. Department of Stomatology, Taipei Veterans General Hospital; 5. Department of Surgery, Taipei Veterans General Hospital; 6. Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital; 7. Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital; 8. Institute of Traditional Medicine, National Yang Ming Chiao Tung University; 9. Division of Hematology, Department of Medicine, Taipei Veterans General HospitalShow moreShow less
FAQ
How long does LEUKEMIA & LYMPHOMA take to review a manuscript?
As of 2026-11-19, CrushSCI has 21 complete review records for LEUKEMIA & LYMPHOMA. The fastest paper went from submission to acceptance in 2 days (The role of radiotherapy in bridging to CAR T-cell therapy for high-grade B-cell lymphoma, received 2026-06-19, accepted 2026-06-21); the slowest took 195 days. The average is 78.1 days and the median is 69 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
